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Emotion dysfunction has long been considered a cardinal feature across psychotic
disorders, including schizophrenia and affective psychosis. However, few studies have
used objective markers of emotional function to compare psychotic disorders to one
another, and fewer studies have examined such markers within a longitudinal framework.
Here, we examine one objective marker of emotional responsivity, the late positive
potential (LPP), which is a centro-parietal event-related potential (ERP) that tracks the
dynamic allocation of attention to emotional vs. neutral stimuli. We used the LPP to
characterize abnormal emotional responsivity by relating it to negative, depressive, and
psychotic symptoms among two clinical groups: individuals diagnosed with affective
psychosis and individuals with schizophrenia. We also used a long-term longitudinal
framework, examining concurrent associations between LPP amplitude and symptom
severity, as well as prospective associations with symptoms 4 years later. Participants
were 74 individuals with psychotic illness: 37 with schizophrenia spectrum disorders and
37 with a primary affective disorder (psychotic bipolar disorder, psychotic depression).
There were no mean-level differences in LPP amplitude between the schizophrenia
spectrum and primary affective psychosis group. In the primary affective psychosis
group, reduced LPP amplitude was associated with greater depressive, negative, and
psychotic symptom severity, both concurrently and at follow-up; associations between
LPP and symptoms were not observed within the schizophrenia spectrum group. This
pattern of results suggests that the neural correlates of emotion dysfunction may differ
across psychotic disorders. One possibility is that schizophrenia is characterized by a
decoupling of symptom severity and emotional processing. Such findings underscore
the importance of analyzing transdiagnostic samples to determine common or specific
symptom relationships across various patient populations.
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INTRODUCTION
Emotion dysfunction is present in various forms across psychotic
disorders, manifesting as negative (e.g., flattened affect), and
depressive symptoms (e.g., anhedonia), and even potentially
contributing to psychotic symptoms (e.g., paranoia). However, it
is currently unclear whether abnormal emotional processes differ
across psychotic disorders, and whether emotional processes
show differential relationships to symptoms, potentially yielding
clinically distinct phenotypes. For example, it is unclear whether
emotional processes show differential relationships to symptoms
for individuals diagnosed with a primary affective disorder (e.g.,
major depressive disorder or bipolar disorder) with psychosis
compared to those diagnosed with a schizophrenia spectrum
disorders. In order to answer such questions, one recent push
in clinical science has been the identification of objective
neural markers which demonstrate relationships with symptoms
(1, 2). Such markers have the potential to objectively index
symptom severity, assist in differential diagnosis, and aid in
further understanding the mechanisms that underlie emotional
disturbances across psychotic disorders (1–3).
One potential neural marker for emotional dysfunction is
the Late Positive Potential (LPP). The LPP is an event-related
potential (ERP) component typically evident ∼300ms after
stimulus onset and at centro-parietal sites. LPP amplitude
is increased following pleasant and unpleasant compared to
emotionally neutral stimuli, including pictures, words, and faces
(4–9). The LPP is thought to index sustained attention to
emotionally-salient stimuli (10, 11), and thus may be particularly
relevant to symptoms of psychiatric disorders that relate to
emotion dysfunction (9). Indeed, several reports examining the
LPP in psychiatric populations have suggested that it is associated
with depressive symptoms (12–15). For example, LPP amplitude
to threatening and rewarding pictures was shown to be reduced
in depressed individuals compared to controls (15). Foti and
colleagues reported similar findings of lower LPP amplitude to
threatening faces in depressed individuals compared to controls
(12). Further, some evidence suggests those at-risk for developing
depression demonstrate reduced LPP amplitude to pleasant,
unpleasant, and neutral stimuli when compared to lower-risk
samples (14, 16). In regards to schizophrenia, LPP amplitude
to pleasant, but not unpleasant pictures has been found to be
reduced in those with schizophrenia vs. controls (13). However,
there is also evidence of normative LPP amplitude to affective
pictures among those with schizophrenia (17). Thus, consistent
evidence suggests lower LPP compared to controls in those with
primary affective disorders while evidence for lower LPP in
schizophrenia spectrum disorders is less consistent.
While previous reports have been informative in establishing
LPP-to-symptom associations within particular diagnostic
categories, few studies have examined the LPP across psychotic
disorders. In one exception, Horan and colleagues measured
LPP during a motivational gradient task where cues signaling
potential monetary gain or loss appeared to loom progressively
closer to the observer (18). They found differences in temporal
dynamics of the LLP between individuals with bipolar disorder
and those with schizophrenia. Specifically, the bipolar group
was characterized by an early escalation of LPP during
cue presentation, whereas the schizophrenia group showed
diminished escalation of LPP to either cue (18). While this
study was informative in further understanding differences
in the temporal dynamics of motivational experience across
psychotic disorders, additional samples including a wider variety
of psychotic disorders could be useful in better understanding
how emotional processes might differ across affective psychosis
and schizophrenia spectrum disorders. In addition, the majority
of studies assessing LPP in psychiatric populations have been
cross-sectional. Such studies are limited in their ability to
determine whether abnormalities in LPP are shaped by current
symptoms, or if such deficits are more enduring or trait-like.
Thus, longitudinal designs are needed to better characterize the
nature of LPP deficits and how they may differ across various
psychotic disorders (19).
In the current study, we examined relationships between
LPP and symptoms of emotional dysfunction within a clinically
heterogeneous sample of individuals with psychotic illness. To
test the potential transdiagnostic nature of LPP-to-symptom
relationships, we contrasted two groups: individuals with
schizophrenia spectrum disorders and individuals with a
primary affective disorder with psychosis (i.e., psychotic bipolar
disorder, psychotic depression). We also utilized a longitudinal
approach, examining the relationships between LPP amplitude
and concurrent symptom severity as well as symptom severity at
a 4-year follow-up. Using these data, we tested two competing
hypotheses: (1) Across psychotic disorders, the LPP would
demonstrate both cross-sectional and lagged associations of
similar magnitude with depressive, negative, and psychotic
symptoms, consistent with transdiagnostic, temporally stable
(i.e., trait-like) association; (2) LPP amplitude may differ between
schizophrenia and affective psychosis (i.e., lower LPP amplitude
in affective psychosis) and LPP-to-symptom relationships exhibit
diagnostic specificity with more robust associations in those
with a primary affective disorder with psychosis than with
a schizophrenia spectrum disorder. This second hypothesis is
consistent with strong evidence of diminished LPP in those with
major depressive disorder (12, 15), but inconsistent with previous
work in schizophrenia (20).
METHODS
Participants
Participants were recruited from the Suffolk County Mental
Health Project (21, 22), an epidemiologic longitudinal study
of first admission psychosis. The sampling frame consisted of
consecutive first admissions with psychosis to the 12 psychiatric
inpatient facilities in Suffolk County, N.Y., from 1989 to 1995.
We specifically included individuals within the sample that met
diagnostic criteria for schizophrenia, schizoaffective disorder,
bipolar disorder with psychosis, or major depressive disorder
with psychosis, at a study session 15 years after first admission.
The current manuscript is one of multiple published with data
collected from this cohort (23–27). Inclusion criteria were: (1)
presence of psychosis; (2) IQ > 70; (3) age between 15 and 60
years at admission; (4) resident of Suffolk County; (5) ability
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to provide informed consent. This study was approved by the
Institutional Review Board at Stony Brook University. EEG was
collected ∼15 years after first admission from 74 participants:
37 participants with 10-year follow-up consensus diagnoses
of schizophrenia spectrum disorders (SZ: 23 schizophrenia,
14 schizoaffective disorder) and 37 participants with affective
psychosis (AP: 27 bipolar disorder, 10major depressive disorder).
Across our sample of 74 individuals, we had ∼95% power
to detect an effect size of f 2 = 0.15 in a model with three
independent variables. Similar effect sizes were found between
depression symptom severity and LPP to threatening compared
to neutral faces across a sample of individuals with major
depressive disorder and healthy controls (12).
Although schizoaffective disorder is characterized by
prominent affective disturbances, we included these individuals
within the schizophrenia spectrum disorders group instead of the
primary affective psychosis group. Previous work has suggested
that schizoaffective disorder is better characterized as part of the
schizophrenia spectrum than of primary mood pathology (28).
Clinical Assessment
Clinical assessments were conducted concurrently with EEG
acquisition (i.e., 15 years after first admission) and at 19-year
follow-up. At each assessment, participants were evaluated by
master’s level interviewers using the Structured Clinical Interview
for DSM-IV-TR Axis I Disorders (SCID-IV) (29), the Scale for
the Assessment of Positive Symptoms (SAPS) (30), and the Scale
for the Assessment of Negative Symptoms (SANS) (31). For the
SAPS and SANS, four subscales were identified: reality distortion
and disorganization, avolition, and inexpressivity (32). Current
depressive symptom severity was operationalized by summing
scores for the nine criterion A items for current major depressive
disorder on the SCID-IV administered without skip-outs. Items
were scored on a 1–3 scale, and the SCID Depression score range
from 9 to 27 (33). Finally, a measure of general cognitive ability,
reading subtest of theWide Range Achievement Test-3rd Edition
(WRAT-3) (34), was collected at the 19-year time point.
Stimulus Materials and Task
Participants passively viewed 130 images selected from the
NimStim set (35)1. Twenty-six images were presented for each
of five facial expressions: happy, sad, angry, afraid, and neutral.
These images depicted 26 different actors (13 male, 13 female),
such that each actor appeared for each of the five emotional face
categories2. Each face was presented once, in a pseudorandom
order for each participant. Images were presented for 1,000ms,
followed by an inter-trial interval that varied randomly from
1,000 to 1,500ms. Participants were instructed to simply view the
images.
1Development of theMacBrain Face Stimulus Set was overseen by Nim Tottenham
and supported by the John D. and Catherine T. MacArthur Foundation Research
Network on Early Experience and Brain Development. Please contact Nim
Tottenham at tott0006@tc.umn.edu for more information concerning the stimulus
set.
2The NimStim actors used were: 1, 2, 3, 5, 7, 8, 9, 10, 11, 12, 14, 17, 18, 20, 22, 23,
24, 25, 26, 27, 30, 34, 37, 38, 39, and 40.
EEG Recording, Processing, and Data
Reduction
EEG was recorded using the Active Two BioSemi System,
sampled at 1,024Hz using 34 scalp electrodes and two mastoid
electrodes. The electro-oculogram was recorded from four facial
electrodes. Oﬄine analysis was performed using Brain Vision
Analyzer software (Brain Products). Data were re-referenced to
the mastoid average and band-pass filtered from 0.1 to 30Hz.
The EEG was segmented on each trial in a window of −200
to 1,000ms surrounding image onset, and correction for blinks
and eye movements was performed using a regression method
(36). Artifact rejection was performed using a semi-automated
procedure. Artifacts were defined as a voltage step of more than
50 µV, a difference of 300 µV within a trial, or a maximum
difference of <0.5 µV within a 100-ms window; additional
artifacts were identified manually. Segments were averaged
separately for each image category and baseline corrected relative
to the 200-ms pre-stimulus interval. The LPP was scored as the
average activity from 400 to 1,000ms at electrode site Pz (where
the response was maximal), similar to previous reports (37–39).
A difference score was calculated by subtracting neutral LPP from
each emotional stimulus category (i.e., happy, sad, afraid, angry),
and these difference scores were used in all analyses. Finally,
the Average LPP was created by averaging LPP difference scores
across all four emotion categories.
Data Analysis
Relationships between symptom severity (SAPS Reality
Distortion, SAPS Disorganization, SANS Avolition, SANS
Inexpressivity, and SCID depression) at each assessment point
(concurrent and follow-up) and LPP difference scores were
examined across the entire sample using separate regression
models. Specifically, individual LPP difference scores were
entered as the dependent variable and symptoms, group (coded:
0.5 for schizophrenia and −0.5 for affective psychosis), and their
interaction were entered as independent variables. Altogether,
the main analysis consisted of ten separate regressions, each
including either a cross-sectional or follow-up symptom variable.
Regression models aimed to quantify the association between
LPP and symptom variables and not the prediction of LPP
by symptoms, per se. A false discovery rate (FDR) correction
was implemented to control for multiple comparisons within
symptom clusters (40). Specifically, four FDR clusters were
used (1) Cross-sectional mood including SANS Inexpressivity,
SANS Avolition, and SCID Depression; (2) Cross sectional
psychosis: SAPS Reality Distortion and SAPS Disorganization;
(3) Follow-up mood: SANS Inexpressivity, SANS Avolition,
and SCID Depression; (4) Follow-up psychosis: SAPS Reality
Distortion and SAPS Disorganization.
RESULTS
Demographics
The affective psychosis and schizophrenia spectrum groups were
similar in regards to demographic variables (Table 1). Relative
to the affective psychosis group, individuals in the schizophrenia
spectrum group were more likely to be prescribed antipsychotic
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TABLE 1 | Demographics.
SZ (N = 37) AP (N = 37) Statistic p-value
Age 44.9 ± 7.8 44.3 ± 9.3 t = 0.3 0.76
Gender (% Male) 56.80% 59.50% χ2 = 0.1 0.81
Ethnicity χ2 = 1.4 0.7
% White 13.50% 5.40%
% Black 8.10% 8.10%
% Hispanic 75.70% 83.80%
% Asian 2.70% 2.70%
Medication Status χ2 = 18.8 <0.001




Disorganization Subscale 3.3 ± 5.3 1.7 ± 3.1 t = 1.7 0.11
Reality Distorting Subscale 3.2 ± 6.0 1.1 ± 3.9 t = 1.8 0.08
SANS
Avolition Subscale 13.7 ± 8.1 4.81 ± 6.4 t = 5.2 <0.001
Inexpressivity Subscale 5.2 ± 7.1 1.78 ± 3.8 t = 2.6 0.01
SCID Depression Sum 11.1 ± 2.7 12.0 ± 3.9 t = −1.1 0.27
Symptom Severity
(Follow-up - 4 years later)
SAPS
Disorganization Subscale 6.0 ± 7.5 3.0 ± 4.6 t = 2.0 0.048
Reality Distorting Subscale 8.6 ± 12.9 1.1 ± 2.4 t = 3.4 0.002
SANS
Avolition Subscale 15.8 ± 9.4 8.4 ± 7.0 t = 3.7 <0.001
Inexpressivity Subscale 10.3 ± 9.7 2.7 ± 4.5 t = 4.1 <0.001
SCID Depression Total 11.5 ± 3.8 12.5 ± 4.5 t = −1.0 0.34
WRAT-3 45.3 ± 6.9 47.2 ± 5.3 t = −1.3 0.21
SANS, Scale for the Assessment of Negative Symptoms; SAPS, Scale for the Assessment
of Positive Symptoms; SCID Depression, Sum of SCID Depression Criterion A Scores. For
these scales higher scores indicate greater impairment.
medications and showed more severe positive and negative
symptoms, although not more severe depression. Significantly
more variance was found in cross-sectional and lagged negative
and positive symptoms but not depressive symptoms (see
Supplemental materials for measures of variance; Table S9).
Group Differences
Grand average ERP waveforms are presented in Figure 1. No
group differences were observed between affective psychosis
and schizophrenia spectrum groups in LPP difference scores
(Table 2). Antipsychotic medication also did not have a
significant relationship to LPP (Table S1). In light of the similar
mean-level LPP amplitude across groups, subsequent analyses
focused on the Average LPP variable as a broader index of
emotional reactivity (see the Supplemental Materials Table S2 for
analyses conducted within emotion category).
Cross-Sectional Associations With
Symptoms
Table 3A describes the main effects of symptoms, group,
and their interaction for each regression model (see Figure 2
for scatterplots; see Figure S1 for scatterplots illustrating
relationship for SZ and SZA separately). Across these regression
models, significant group effects were not observed. A
significant symptom effect for psychotic symptoms (SAPS
Reality Distortion) was observed such that greater symptom
severity was associated with lower LPP amplitude, but all other
symptom effects were non-significant. Broadly, associations
between LPP difference score amplitude and symptom severity
were more robust in the affective psychosis group compared to
the schizophrenia group. Specifically, significant interactions
between symptom variables and diagnostic group (coded:
0.5 for schizophrenia and −0.5 for affective psychosis) were
observed for depressive (SCID Depression), negative (SANS
Avolition), and psychotic (SAPS reality distortion) symptoms
suggesting more robust negative associations between LPP
and symptoms in the affective psychosis compared to the
schizophrenia group. All significant interactions maintained
significance when controlling for multiple comparisons (see
Table S3 of Supplemental Materials for FDR-corrected q-values).
The interaction between expressive negative symptoms (SANS
Inexpressivity) and group was trend-level, and the interaction
between disorganized symptoms (SAPS disorganization) and
LPP was not significant (Table 3A). Regression models met the
assumptions of normality of the residuals (See Tables S4, S5 of
Supplemental Materials for skewness, kurtosis, and Shaprio-Wilk
tests of the residuals for each model).
Symptoms at 4-Year Follow-Up
Table 3B describes the main effects of symptoms (measured 4
years following ERP acquisition), group, and their interaction
for each regression model (see Figure 2 for scatterplots; see
Figure S1 for scatterplots illustrating relationship for SZ and
SZA separately). Across these regression models, no significant
effects of group were observed. A significant symptom effect
for psychotic symptoms (SAPS Reality Distortion) and a trend-
level effect for SANS Avolition were observed such that greater
symptom severity was associated with lower LPP amplitude.
All other symptom effects were non-significant. Significant
interactions between symptom variables and diagnostic group
(coded: 0.5 for schizophrenia and −0.5 for affective psychosis)
were observed for negative (SANS Avolition) and psychotic
(SAPS reality distortion) symptoms suggesting more robust
negative lagged associations between LPP and symptoms
in the affective psychosis compared to the schizophrenia
group. Associations between LPP Amplitude and depressive,
disorganized, or inexpressive negative symptoms did not
maintain significance at follow-up. When controlling for
multiple comparisons, only the interaction between psychotic
symptoms and groupmaintained significance (seeTable S3 of the
Supplemental Materials for FDR-corrected q-values). Regression
models met the assumptions of normality of the residuals (See
Tables S4, S5 of Supplemental Materials for skewness, kurtosis,
and Shaprio-Wilk tests of the residuals for each model).
Further Analysis of LPP Difference Scores
In order to aid in the interpretation of LPP difference scores,
we conducted supplementary analyses to determine whether
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FIGURE 1 | (Left) LPP Grand Average Waveform, (Right) Scalp Map illustrating LPP activation.
TABLE 2 | Group differences in LPP amplitude.






Angry 0.57 (4.1) 0.65 (4.4) 0.93
Afraid 1.44 (3.17) 1.21 (5.6) 0.84
Sad 0.44 (5.0) 0.67 (4.5) 0.84
Happy 0.64 (4.2) 0.45(3.8) 0.84
Average 0.77 (3.0) 0.74 (3.9) 0.97
SD, standard deviation.
neural response to emotional category or neutral category
was driving the observed relationships between LPP difference
scores and symptoms (Tables S6a,b of Supplemental Materials).
Specifically, we conducted multiple regressions where either LPP
to averaged emotion faces or to neutral faces was the dependent
variable and symptoms, group, and their interaction were the
independent variable. For positive and depressive symptoms,
significant interactions between symptoms and group were
largely driven by increased LPP amplitude to neutral stimuli. For
negative symptoms, significant interactions between symptoms
and group were driven by both increased LPP amplitude to
neutral stimuli and decreased LPP amplitude to emotional
stimuli (Table S6).
Role of Antipsychotic Medications
In order to better understand the role of antipsychotic dose
in the aforementioned effects, we conducted similar multiple
regressions to those described above but entered chlorpromazine
(CPZ) equivalent dose as an additional independent variable
[calculated using (41) documenting a score of zero for individuals
not currently prescribed antipsychotics]. Critically, CPZ dose
was not significantly associated with LPP in any of these
models (see Tables S7, S8 of Supplemental Materials). Further,
all aforementioned significant symptom by group interactions
TABLE 3a | Multiple Regressions illustrating the cross-sectional association
between Average LPP Difference Scores and symptoms, Group, and the
interaction of group and symptoms.
A.) Depression Regression Beta SE t-value p-value
Group 0.139 0.763 0.182 0.856
SCID Depression −0.194 0.121 −1.599 0.114
Group x Depression −0.661 0.242 −2.732 0.008
B.) Avolition Regression Beta SE t-value p-value
Group −0.996 0.94 −1.06 0.293
SANS Avolition −0.11 0.057 −1.942 0.056
Group x Avolition −0.251 0.113 −2.218 0.03
C.) Inexpressivity Regression Beta SE t-value p-value
Group −0.6 0.856 −0.701 0.486
SANS Inexpressivity −0.168 0.085 −1.973 0.053
Group x Inexpressivity −0.331 0.171 −1.941 0.056
D.) Disorganization Regression Beta SE t-value p-value
Group −0.247 0.845 −0.292 0.771
SAPS Disorganization −0.129 0.11 −1.178 0.243
Group x Disorganization −0.189 0.219 −0.86 0.393
E.) Reality Distortion Regression Beta SE t-value p-value
Group −0.583 0.788 −0.739 0.462
SAPS Reality Distortion −0.267 0.084 −3.178 0.002
Group x Reality Distortion −0.426 0.168 −2.537 0.013
Group was coded: 0.5 for schizophrenia and -0.5 for affective psychosis.
remained significant when including CPZ into the statistical
model (see Tables S7, S8 of Supplemental Materials).
DISCUSSION
The goal of the current study was to test the hypothesis
of transdiagnostic relationships between LPP amplitude
and symptoms of emotional dysfunction, across putatively
distinct psychotic illnesses. We found that significantly greater
associations between LPP amplitude and symptom severity in
individuals with affective psychosis compared to schizophrenia
spectrum disorders for negative, depressive, and psychotic
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FIGURE 2 | Scatterplots illustrating relationships between symptom severity and LPP difference scores averaged across emotion categories.
TABLE 3b | Multiple regressions describing the lagged associations between
Average LPP Difference Scores and Symptoms, Group, and the interaction of
group and symptoms.
A.) Depression Regression Beta SE t-value p-value
Group −0.229 0.856 −0.268 0.789
SCID Depression −0.014 0.105 −0.133 0.894
Group x Depression −0.2 0.211 −0.949 0.346
B.) Avolition Regression Beta SE t-value p-value
Group −0.953 0.899 −1.06 0.293
SANS Avolition −0.098 0.052 −1.896 0.062
Group x Avolition −0.228 0.104 −2.202 0.031
C.) Inexpressiviity Regression Beta SE t-value p-value
Group −0.575 0.999 −0.576 0.567
SANS Inexpressivity −0.046 0.073 −0.63 0.531
Group x Inexpressivity −0.239 0.146 −1.631 0.108
D.) Disorganization Regression Beta SE t-value p-value
Group −0.5 0.878 −0.569 0.571
SAPS Disorganization −0.087 0.077 −1.121 0.266
Group x Disorganization −0.101 0.155 −0.649 0.518
E.) Reality Distortion Regression Beta SE t-value p-value
Group −2.231 1.218 −1.831 0.072
SAPS Reality Distortion −0.268 0.123 −2.186 0.032
Group x Reality Distortion −0.668 0.245 −2.723 0.008
Group was coded: 0.5 for schizophrenia and -0.5 for affective psychosis.
symptoms, thereby suggesting diagnostic specificity for these
LPP-symptom relationships. Further, LPP amplitude showed
some evidence of specificity to specific symptoms as no
significant associations were observed between LPP amplitude
and symptoms of disorganization.
Associations between reduced LPP amplitude and symptom
severity in the affective psychosis group are consistent with
several previous reports in non-psychotic depressed samples
(12, 15) or in those at risk for developing depression (14, 16, 42).
The current report extends prior findings by demonstrating LPP-
to-symptom associations in those with psychotic disorders with
a primary affective component suggesting that previous findings
may generalize to both psychotic and non-psychotic forms of
the illness, and further shows that these relationships for some
symptom variables (i.e., avolition) persist over years. However,
the current report also suggests that the LPP may be indexing
more state-like compared to trait-like variability for depressive
symptoms. Future studies of the LPP inmajor depressive disorder
may benefit from more directly examining individuals with and
without psychosis in the same sample, and further may benefit
isolating avolition as a particularly relevant symptom dimension
separate from global depression severity.
While LPP in individuals with affective psychosis was
related to symptom severity measures, LPP was not related to
any symptom measures in the schizophrenia group. This is
consistent with previous studies who find similar LPP amplitude
between healthy controls and those with schizophrenia, as well
as studies that fail to find significant relationships between
symptom severity and LPP in schizophrenia (13, 17). This
raises interesting questions as to why LPP amplitude in
those with schizophrenia appears insensitive to variations in
clinical symptom measures. One possible explanation may
be that the psychological and neural mechanisms that give
rise to affective disturbance in schizophrenia may differ from
affective psychosis. For example, in the moment emotional
response may be intact in schizophrenia but decoupled from
the retrospective reports of emotional experience measured via
clinical interview, potentially due to difficulties encoding and
retrieving affective experience (43, 44). In contrast, retrospective
reports of emotional experience measured via clinical interview
may be better coupled with in-the-moment emotional response
in affective psychosis, potentially due to more intact cognitive
ability in these individuals when compared to those with
schizophrenia (45, 46).
Supplementary analyses revealed that associations between
LPP and psychotic and depressive symptoms were largely driven
by a larger LPP to neutral stimuli, a pattern that was also
evident in the SZ group. In contrast, associations between LPP
difference scores and negative symptoms were characterized by
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blunting of the discrimination between neutral and emotional
faces. The associations between psychotic symptoms and
neutral LPP in the current report are largely consistent with
previous literature, including neuroimaging studies, which report
enhanced activation of the limbic system to neutral faces in those
at-risk for developing psychosis (47). Kapur and others have
proposed that psychosis is associated with aberrant attributions
of motivational salience to neutral stimuli (48). The current
associations between neutral LPP and psychotic symptoms are
consistent with this account. Further, there is some evidence that
blunted amygdala responsivity to emotional faces in individuals
with major depressive disorder is driven by increased reactivity
to neutral faces and that this increased reactivity normalizes with
treatment (49). The current results showing that LPP to neutral
faces correlates with depressive symptoms are consistent with this
account.”
Limitations
The absence of a healthy comparison group limited our ability
to interpret group differences between psychiatric groups and
healthy controls. However, the aim of the current manuscript
was to examine associations between the LPP and symptoms
concurrently and years later across psychotic disorders. Further,
previous studies have the LPP largely intact in schizophrenia
making a healthy control group potentially less informative.
Thus, a healthy comparison group was not integral to the
examination of the aims of the current study. Second, although
we found robust associations between symptoms, in our affective
psychosis group, and LPP amplitude, we did not have the
statistical power to examine such relationships within individual
diagnoses (i.e., major depressive disorder, bipolar disorder). It
may be the case that such relationships demonstrate important
diagnostic group differences within affective psychosis and this
remains an important question for future work. Further, may
be important to separately analyze those with schizoaffective
disorder. Finally, many of our participants were taking
medications that have known influences on emotional processes,
and the number of individuals prescribed such medications
differed between groups. While medication status did not
significantly modulate the relationship between symptoms and
LPP amplitude, it remains possible that absence of effects in
schizophrenia group may be due to the history of exposure
to antipsychotics rather than being characteristic of the illness
itself.
Summary
We found modest evidence for negative associations between
depressive and psychotic symptom severity and LPP amplitude.
However, individuals with primary affective psychosis largely
drove these correlations. Specifically, we found robust concurrent
and lagged correlations of LPP with symptoms of psychotic,
depressive, and negative symptoms not among individuals with
schizophrenia but instead among individuals with a primary
affective disorder with psychosis, providing some evidence
for diagnostic specificity in the neural correlates of emotion
dysfunction. These data are consistent with previous findings of
robust correlations between depressive symptoms and reduced
LPP amplitude in major depression (12), and also consistent
with previous reports showing an absence of symptom-to-LPP
relationships in those with schizophrenia (13, 17). Our results
point to the possibility that similarly assessed symptom domains
may arise from different psychological and neural mechanisms
across psychotic disorders, underscoring the importance in
studying multiple disorders together to further understand
psychosis.
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